Roche’s Tecentriq Shows Survival In Triple-Negative Breast Cancer, For Some
Executive Summary
Treatment with Tecentriq helped some patients with aggressive metastatic triple-negative breast cancer to live significantly longer, those that responded to treatment, according to data presented at AACR.
You may also be interested in...
Roche Digs In To Early Breast Cancer With New Perjeta Approvals
Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.